
Dual GIP + GLP-1 receptor activity
Tirzepatide acts on both GIP and GLP-1 receptors, signaling pathways involved in appetite regulation and metabolic function.

Same price at every dose · your provider sets the dose
$627 today for 3 months. Renews at $627 every 3 months until you cancel.
Prescription items are subject to clinician review before dispensing. After checkout you will complete a medical intake form. A licensed physician reviews it, and if you are approved, your medication ships. Your clinician sets the exact dose during that review.
This is a prescription product and requires an evaluation by a licensed provider. Purchase does not guarantee a prescription, and if you are not approved you will not be charged for medication.
Compounded formulations are prepared by licensed 503A pharmacies and are not FDA-approved for safety or efficacy. Availability varies by state. Not for use by anyone under 18. This information is not medical advice — talk to your provider about risks, side effects and interactions.
Multi-month plans renew automatically at the end of the term until cancelled. Cancel any time before renewal from your account.
Full safety information
Tirzepatide acts on both GIP and GLP-1 receptors, signaling pathways involved in appetite regulation and metabolic function.

These pathways help regulate hunger and food intake. Your response can vary, and your clinician determines whether tirzepatide is appropriate for your treatment plan.

Tirzepatide also affects insulin and glucagon signaling in a glucose-dependent manner as part of its metabolic activity.

Tirzepatide may be considered by a licensed clinician as part of an individualized weight-management plan.
Your treatment plan is based on your medical history, goals, response and tolerability. Your clinician determines the appropriate medication and dose.
Individual results vary.
Treatment is individualized rather than based on a guaranteed timeline.
Your clinician may adjust your prescribed dose over time based on your response and how well you tolerate treatment.
Gastrointestinal symptoms such as nausea, diarrhea, vomiting, constipation or abdominal discomfort can occur with tirzepatide. Contact your clinician if symptoms are persistent, severe or concerning.
Continue following the treatment, nutrition, activity and follow-up plan recommended by your clinician. Changes in appetite, tolerability and treatment response vary from person to person.


Your labs show why — and shape what comes next

Lower-dose tirzepatide to support metabolic function.
Join the waitlist

Lower-dose semaglutide to support metabolic health.
Join the waitlist

A once-daily oral GLP-1 for chronic weight management.
Join the waitlist

A needle-free oral GLP-1 that helps regulate appetite.
Join the waitlist